Prof. PeptideProf. Peptide
Guide

How is tesamorelin dosed?

Tesamorelin is FDA-approved under two current brand names — Egrifta WR and Egrifta SV — for one specific indication. This page reads both current prescribing informations directly, the two Phase 3 trials both labels cite, and the adverse events reported at the approved dose.

Topic: Reading tesamorelin’s FDA prescribing information, for both current formulations

Audience: Anyone comparing a tesamorelin dose figure against its actual label or trial source

Reading time: 8–10 minutes

FDA-approved for one indication only

Tesamorelin is approved as Egrifta WR and Egrifta SV for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy — not for weight loss, general fat reduction, or anti-aging use. Both labels state it is not indicated for weight loss management and that long-term cardiovascular safety has not been established. Every figure on this page is read from the current prescribing information or a specific trial — not a recommendation for off-label use.

What tesamorelin is, and its one approved indication

Tesamorelin is a growth hormone-releasing factor (GHRF/GHRH) analog. It is approved by the FDA under two current brand names — Egrifta WR (11.6 mg/vial) and Egrifta SV (2 mg/vial) — for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. Both labels state this explicitly as a limitation of use: tesamorelin is not indicated for weight loss management, and long-term cardiovascular safety has not been established.

Egrifta WR and Egrifta SV are explicitly stated as not substitutable — each formulation has its own dose, its own diluent, and its own reconstitution and storage instructions, read separately below. The tesamorelin profile covers the mechanism and broader research context in more depth; this page exists specifically to read both current labels’ dosing side by side.

What the two current labels specify

Both tables below are read directly from each product’s own current prescribing information on DailyMed — Egrifta WR and Egrifta SV are separate documents, separate approvals, and (per both labels) not substitutable for each other.

Egrifta WR (11.6 mg/vial formulation)

StepFigureAs specified by the label
Dose1,280 mcg (1.28 mg; 0.16 mL of reconstituted solution) once dailySubcutaneous injection in the abdomen, rotating sites; not the navel, scars, or bruises.
Reconstitution1 vial + 1.3 mL Bacteriostatic Water for Injection, USPSwirl, do not shake. One reconstituted vial supplies 7 daily doses; discard 7 days after mixing.

Egrifta SV (2 mg/vial formulation)

StepFigureAs specified by the label
Dose1,400 mcg (1.4 mg; 0.35 mL of reconstituted solution) once dailySubcutaneous injection in the abdomen, rotating sites; not the navel, scars, or bruises.
Reconstitution1 vial + 0.5 mL Sterile Water for InjectionRoll gently 30 seconds, do not shake. Administer immediately after reconstitution; discard any unused solution — do not freeze or refrigerate the reconstituted solution.

Neither label states a missed-dose rule.

Searched in full, neither the Egrifta WR nor the Egrifta SV prescribing information contains missed-dose instructions of the kind Wegovy’s or Ozempic’s labels carry. This page states that absence rather than inferring a rule from another product’s label.

The Prof. Peptide dosage calculator converts between milligram figures and syringe units for a given reconstitution; it performs the arithmetic and does not set a schedule.

What the trials administered

Neither WR nor SV has its own dedicated efficacy trial. Both labels state that safety and effectiveness were established using the original EGRIFTA formulation (1 mg/vial, 2,000 mcg (2 mg) once-daily dose) in the two trials below, and that WR’s and SV’s own approvals rest on demonstrated comparable bioavailability to that original 2,000 mcg (2 mg) dose — a bridge, not a new efficacy trial at 1,280 mcg (1.28 mg) or 1,400 mcg (1.4 mg) specifically.

Both trials are graded against Prof. Peptide’s standing citation convention — a claim is attributed when it resolves to a named, checkable source. Both grade as attributed, cited directly in both current labels’ Clinical Studies section.

Study 1

NCT00123253

Design: 26-week Main Phase, multicenter, randomized, double-blind, placebo-controlled trial in HIV-infected patients with lipodystrophy and excess abdominal fat, followed by a 26-week blinded Extension Phase.

Arms: 412 participants randomized to the original EGRIFTA (1 mg/vial formulation) 2,000 mcg (2 mg) once daily (N=273) or placebo (N=137), subcutaneous injection.

Endpoint reported: Visceral adipose tissue (VAT) change at week 26 (CT scan, L4-L5 level, intent-to-treat with last observation carried forward): −27 cm² (EGRIFTA) versus +4 cm² (placebo), mean treatment difference −31 cm² (95% CI −39, −24); percent change −18% versus +2%, mean treatment difference −20 percentage points (95% CI −24, −15). IGF-1 rose by a mean of 107 ng/mL versus −15 ng/mL on placebo.

Attributed — cited directly in both Egrifta WR's and Egrifta SV's own Clinical Studies section (14), registered with a checkable NCT number independently confirmed against ClinicalTrials.gov.

Study 2

NCT00435136

Design: 26-week Main Phase, multicenter, randomized, double-blind, placebo-controlled trial in HIV-infected patients with lipodystrophy and excess abdominal fat, followed by a 26-week blinded Extension Phase.

Arms: 404 participants randomized to the original EGRIFTA (1 mg/vial formulation) 2,000 mcg (2 mg) once daily (N=270) or placebo (N=126), subcutaneous injection.

Endpoint reported: Visceral adipose tissue change at week 26: −21 cm² (EGRIFTA) versus −0 cm² (placebo), mean treatment difference −21 cm² (95% CI −29, −12); percent change −14% versus −2%, mean treatment difference −12 percentage points (95% CI −16, −7). IGF-1 rose by a mean of 108 ng/mL versus +3 ng/mL on placebo.

Attributed — cited directly in both current labels' Clinical Studies section, registered with a checkable NCT number independently confirmed against ClinicalTrials.gov.

Warnings and adverse events

Neither the Egrifta WR nor the Egrifta SV prescribing information carries a boxed warning. Both carry a Warnings and Precautions section covering: increased risk of neoplasms (the label calls for preexisting malignancy to be inactive and its treatment complete before starting, and for stopping if malignancy recurs); elevated IGF-1 (monitored during therapy, with stopping considered at persistent elevation); fluid retention (edema, arthralgia, carpal tunnel syndrome); glucose intolerance or diabetes mellitus (increased risk of developing diabetes versus placebo, hazard ratio 3.3); hypersensitivity reactions; and injection site reactions.

Table 1 of the label (combined across both pivotal studies) reports adverse reactions occurring in 1% or more of tesamorelin-treated patients and more frequently than on placebo, during the 26-week placebo-controlled phase:

Adverse reactionPlacebo (N=263)Tesamorelin (N=543)
Injection site reaction (combined)6%17%
Arthralgia11%13%
Pain in extremity5%6%
Myalgia2%6%
Edema peripheral2%6%
Paresthesia2%5%
Hypoesthesia2%4%
Rash2%4%

N=543 reflects the 740 tesamorelin-treated patients across all trials, of whom 543 received tesamorelin during the initial 26-week placebo-controlled phase — matching the figure both labels cite.

How do clinics dose compounded tesamorelin?

Clinics also prescribe compounded tesamorelin off-label, outside the approved HIV indication. Clinics commonly use 1,000 to 2,000 mcg (1 to 2 mg) once a day by subcutaneous injection, usually in the abdomen; the range reported is 750 to 2,000 mcg (2 mg) [6][7][8]. That sits close to the label doses above. This is clinic practice, credited to the clinics that publish it — not a label dose and not advice.

  • Starting dose: two clinics start at 1,000 mcg (1 mg) a day, for the first month or for 2 to 4 weeks, then move to 2,000 mcg (2 mg) [6][8]; one checks IGF-1 at week 8 and cuts the dose if it exceeds 350 to 400 ng/mL [8].
  • Timing: once a day, often at bedtime because growth hormone pulses at night, with the timing left to the prescriber [9]; some clinics give it in the morning [10].
  • Course: this is where clinics differ most from the label. Some cycle it, in 10- to 12-week courses followed by a brief break, or 12 to 16 weeks on and 2 to 4 weeks off [11][8], or give it Monday to Friday only [7]; others run it continuously, for at least 26 weeks or 6 to 12 months [7][10]. Both labels describe continuous once-daily use, reassessed at 26 weeks.
  • Form: some clinics supply it pre-mixed and ready to inject [6]; others as a powder reconstituted with sterile water before use [12].
  • Side effects clinics list for compounded tesamorelin match the label’s: injection-site reactions, joint and muscle aches, fluid retention or swelling in the hands or feet, and tingling or numbness, with nausea and a temporary rise in blood glucose [9][12][13].
  • Monitoring panels clinics publish: IGF-1, fasting glucose or HbA1c, lipids, waist circumference and DXA body composition [13]; IGF-1, a metabolic panel, a blood count, HbA1c and, for men, PSA before starting [12]. Clinics exclude the same groups as the label: active cancer, a disrupted hypothalamic-pituitary axis and pregnancy [13][14].

The tesamorelin profile’s dosing section tabulates each clinic’s published protocol and the prices clinics list.

Compounding and research-grade tesamorelin

Tesamorelin’s compounding-eligibility question is structurally different from a compound with no approved product.

Section 503A of the Federal Food, Drug, and Cosmetic Act treats a bulk drug substance as eligible for compounding if it complies with a USP or NF monograph, is a component of an FDA-approved drug, or appears on FDA’s 503A bulks list. Tesamorelin IS a component of two FDA-approved drugs — Egrifta WR and Egrifta SV — which satisfies that second condition directly, from the label itself. That is a statement about eligibility, not a claim that compounding tesamorelin is therefore routine or unrestricted: 503A’s own operative conditions — a documented drug shortage, or a prescriber-documented clinical difference for a specific patient — govern when a compounding pharmacy may actually rely on that eligibility, and this page has not verified whether either condition currently applies to tesamorelin.

Clinics that prescribe compounded tesamorelin describe it as made by a licensed 503A compounding pharmacy and prescribed off-label after a clinician’s review [7][16]. In sport, the World Anti-Doping Agency’s 2026 Prohibited List names growth-hormone-releasing hormone analogues, including tesamorelin, under S2, prohibited at all times [15].

Research-grade tesamorelin, of the kind sold by the vendors Prof. Peptide tracks elsewhere on this site, is neither the branded Egrifta product nor a verified pharmacy-compounded version of it. It is sold labeled for laboratory research use, not for human administration, and it is not dispensed against a prescription.

FAQ

Is tesamorelin FDA-approved?
Yes — for one specific indication. Tesamorelin is FDA-approved under two brand names, Egrifta WR and Egrifta SV, for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. Both labels state it is NOT indicated for weight loss management, and that long-term cardiovascular safety has not been established. It is the only GHRH-analog compound among the eight recovery/secretagogue compounds Prof. Peptide compared for this guide with a current FDA-approved product.
What is the approved Egrifta dosage?
Egrifta WR (11.6 mg/vial): 1,280 mcg (1.28 mg; 0.16 mL of the reconstituted solution) by subcutaneous injection once daily. Egrifta SV (2 mg/vial): 1,400 mcg (1.4 mg; 0.35 mL of the reconstituted solution) by subcutaneous injection once daily. The two formulations and strengths are explicitly stated as not substitutable — each label's dosage and reconstitution instructions apply only to that formulation.
Are Egrifta WR and Egrifta SV backed by their own separate trials?
No — both are approved on a bioequivalence bridge, not a dedicated efficacy trial of their own. Both labels state that safety and effectiveness were established using the original Egrifta formulation (1 mg/vial, 2,000 mcg (2 mg) daily dose) in two Phase 3 trials, Study 1 (NCT00123253) and Study 2 (NCT00435136), and that WR's and SV's own approvals rest on demonstrated comparable bioavailability to that original 2,000 mcg (2 mg) dose — not on a new efficacy trial at the 1,280 mcg (1.28 mg) or 1,400 mcg (1.4 mg) dose specifically.
What happens if a dose is missed?
Neither current label states a missed-dose rule. Searched in full, neither the Egrifta WR nor the Egrifta SV prescribing information contains missed-dose instructions of the kind Wegovy's or Ozempic's labels carry — this page states that absence rather than inferring a rule from another product's label.
Does tesamorelin carry a boxed warning?
No. Searched in full, neither the Egrifta WR nor the Egrifta SV label contains a boxed warning section. Both labels do carry a Warnings and Precautions section covering increased risk of neoplasms, elevated IGF-1, fluid retention, glucose intolerance or diabetes mellitus, hypersensitivity reactions, and injection site reactions — none of these rise to a boxed warning in either label as currently published.
How do clinics dose compounded tesamorelin?
Mostly close to the label and the trial dose. Clinics prescribing compounded tesamorelin commonly use 1,000 to 2,000 mcg (1 to 2 mg) once a day by subcutaneous injection; the range reported is 750 to 2,000 mcg (2 mg). Two clinics start at 1,000 mcg (1 mg) for the first weeks and raise the dose after checking IGF-1. Where clinics differ from the label is the schedule: some cycle it, in 10- to 16-week courses with breaks, or give it Monday to Friday, while others run it continuously for 6 to 12 months. Both Egrifta labels describe continuous once-daily use, with risk/benefit reassessed at 26 weeks if visceral fat has not been reduced.
Can tesamorelin legally be compounded?
Its compounding eligibility question is structurally different from a compound with no approved product. Section 503A of the FD&C Act treats a bulk drug substance as eligible for compounding if it complies with a USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list — and tesamorelin IS a component of two FDA-approved drugs, Egrifta WR and Egrifta SV, which satisfies that condition directly. That is eligibility, not a statement that compounding tesamorelin is unrestricted: 503A's own operative conditions (a documented drug shortage, or a prescriber-documented clinical difference for a specific patient) govern when a pharmacy may actually rely on that eligibility, and this page has not verified whether either condition currently applies to tesamorelin. Clinics that prescribe it describe it as compounded by a licensed 503A pharmacy and prescribed off-label after a clinician's review.
What does Prof. Peptide's own research-grade tesamorelin fall under, then?
Neither the branded product nor a verified compounded version of it. The vendors Prof. Peptide tracks sell research-grade tesamorelin labeled for laboratory research use, not for human administration and not dispensed against a prescription — a separate category from both Egrifta WR/SV and from any pharmacy-compounded product.

References

  1. Theratechnologies Inc. EGRIFTA WR (tesamorelin) for injection — prescribing information. DailyMed, setid 839334d3-8c1d-4c26-9036-2ab524a6ea75. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75
  2. Theratechnologies Inc. EGRIFTA SV (tesamorelin) for injection — prescribing information. DailyMed, setid 3d783378-b02d-4f19-99dd-0fc91a042224. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224
  3. ClinicalTrials.gov. Study 1, NCT00123253. https://clinicaltrials.gov/study/NCT00123253
  4. ClinicalTrials.gov. Study 2, NCT00435136. https://clinicaltrials.gov/study/NCT00435136
  5. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
  6. Clinic: VitalRx, Tesamorelin protocol (clinical content reviewed by Jonathan Snipes, MD). Cited for its 1 mg (month 1) then 2 mg daily protocol, pre-constituted form and 28-day labs. Read November 6, 2026. https://vitalrx.io/peptide-therapy/tesamorelin
  7. Clinic: Rx Peps Direct, Tesamorelin 0.75, 1 or 2 mg (compounded by a licensed 503A pharmacy). Cited for its three doses, bedtime Monday-to-Friday schedule and at-least-26-week course. Read November 6, 2026. https://www.rxpepsdirect.com/peptides/muscle-growth/tesamorelin
  8. Clinic: True Heal Wellness, Tesamorelin. Cited for its 1 mg start for 2 to 4 weeks then up to 2 mg, the week-8 IGF-1 check (dose cut above 350 to 400 ng/mL) and its 12-to-16-weeks-on, 2-to-4-off cycle. Read November 6, 2026. https://www.truehealwellness.com/peptides-research/tesamorelin
  9. Clinic: Pru, Tesamorelin dosage (updated July 9, 2026). Cited for its timing line and side-effect list. Read November 6, 2026. https://joinpru.com/blog/tesamorelin-dosage
  10. Clinic: Patrick Taylor, MD (Live Vital), Tesamorelin. Cited for once-daily morning dosing and a 6-to-12-month course. Read November 6, 2026. https://www.drpattaylor.com/peptides/tesamorelin
  11. Clinic: Relive Health Houston Memorial, Tesamorelin. Cited for its 10-to-12-week cycle followed by a brief break. Read November 6, 2026. https://relivehealth.com/memorial-houston-tx/peptide-therapy/tesamorelin/
  12. Clinic: Defy Medical, Tesamorelin: the peptide that targets visceral fat. Cited for its route and form, baseline lab panel and side-effect list. Read November 6, 2026. https://www.defymedical.com/blog/tesamorelin-the-peptide-that-targets-visceral-fat/
  13. Clinic: Marek Health, Tesamorelin. Cited for its side effects, exclusions and monitoring panel. Read November 6, 2026. https://marekhealth.com/treatments/tesamorelin
  14. Clinic: Pru, Tesamorelin guide (updated July 9, 2026). Cited for its statement that tesamorelin is avoided in active cancer and in pregnancy. Read November 6, 2026. https://joinpru.com/blog/tesamorelin-guide
  15. World Anti-Doping Agency. The Prohibited List 2026, S2 (valid January 1, 2026; read October 26, 2026, as on the tesamorelin profile). https://www.wada-ama.org/en/prohibited-list
  16. Clinic: Live Vital, Compounded tesamorelin: physician-prescribed. Cited for its statement that compounded tesamorelin may be prescribed, including off-label, when a licensed clinician determines it is appropriate. Read November 6, 2026. https://livevital.io/treatments/tesamorelin

Affiliate disclosure: Prof. Peptide earns a commission on purchases and sign-ups made through its links and codes, at no extra cost to the buyer. Commissions never decide which vendors are listed, how they are ranked or verified, or what Prof. Peptide concludes.

Checked and updated